R-ESHAP regimen
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Etoposide, Solumedrol (Methylprednisolone) High-dose Ara-C (Cytarabine), Platinol (Cisplatin)
Overview
R-ESHAP regimen refers to a salvage regimen consisting of rituximab, etoposide, (Solumedrol, high-dose), cytarabine (Ara-C), and cisplatin (Platinol) used to treat refractory diffuse large B-cell lymphoma.[1]
Regimen
RRituximab
EEtoposide
SHMethypredisolone (Solumedrol), High-dose
ACytarabine (Ara C)
PCisplatin (Platinol)
Indications
References
- ↑ 1.0 1.1 Martín A, Caballero MD, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (2009). “R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome”. Haematologica. 94 (5): 744. doi:10.3324/haematol.2009.006452. PMC 2675691. PMID 19336744.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH